肿瘤科
彭布罗利珠单抗
内科学
临床试验
癌症研究
重症监护医学
无容量
临床实习
作者
Francesco Passiglia,Oriana Commendatore,Milena Vitali,Raffaele Conca
出处
期刊:Future Oncology
[Future Medicine]
日期:2018-06-01
卷期号:14: 41-60
被引量:4
标识
DOI:10.2217/fon-2018-0098
摘要
Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI